Insider · CIK 0001264949
Greg Zante
Files at VKTX (Viking Therapeutics, Inc.). First filing Oct 28, 2024, latest Jan 5, 2026.
Greg Zante files SEC Form 4 as CFO at VKTX (Viking Therapeutics, Inc.). Since Oct 28, 2024, Greg Zante has reported 0 open-market buys worth $0 and 4 open-market sells worth $12M, the latest filed on Jan 5, 2026.
A track record needs three past buys with six months of prices behind them; Greg Zante has 0, so none is measured yet.
The newest scored trade: sold $1.9M of VKTX on Jan 5, 2026, filed Jan 5, 2026, scored 67 (notable). In the last 12 months: 0 buys worth $0 and 2 sells worth $2.1M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VKTX: Viking Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 67Notable | Viking Therapeutics, Inc. | $1.9M 57,661 shares | -23% | +61% from low-24% from high | |
| 49Moderate | Viking Therapeutics, Inc. | $216k 6,185 shares | -3% | +75% from low-53% from high | |
| 47Moderate | Viking Therapeutics, Inc. | $118k 4,266 shares | -2% | +41% from low-64% from high | |
| 37Weak | Viking Therapeutics, Inc. | $10M 131,687 shares | -47% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 3, 2025 | VKTX VIKING THERAPEUTICS, INC. | 4,266 0.00% of outstanding | $118k | Jul 3, 2025 | none |
| Jan 6, 2025 | VKTX VIKING THERAPEUTICS, INC. | 50,309 0.05% of outstanding | $2.2M | Jan 6, 2025 | none |
| Oct 28, 2024 | VKTX VIKING THERAPEUTICS INC | 131,687 0.12% of outstanding | $10M | Oct 28, 2024 | $922k |
Transactions
Every row this insider has filed, 27 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +41,000 | $0.00 | $0 | 215,483 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +32,049 | $0.00 | $0 | 247,532 | Jan 5, 2026 |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -31,961 | $32.30 | $1.0M | 215,571 | Jan 5, 2026 |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -13,900 | $33.38 | $464k | 201,671 | Jan 5, 2026 |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -10,300 | $34.24 | $353k | 191,371 | Jan 5, 2026 |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -1,500 | $32.09 | $48k | 189,891 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +91,000 | $0.00 | $0 | 91,000 | Jan 5, 2026 |
| Oct 27, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +11,117 | $0.00 | $0 | 179,777 | Oct 28, 2025 |
| Oct 28, 2025 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -6,185 | $35.00 | $216k | 173,592 | Oct 28, 2025 |
| Jul 2, 2025 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +7,667 | $0.00 | $0 | 172,926 | Jul 3, 2025 |
| Jul 3, 2025 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share | -4,266 | $27.76 | $118k | 168,660 | Jul 3, 2025 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +12,750 | $7.77 | $99k | 199,802 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +4,251 | $4.68 | $20k | 204,053 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +26,000 | $5.80 | $151k | 230,053 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +51,000 | $8.52 | $435k | 281,053 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -49,672 | $74.56 | $3.7M | 231,381 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -18,620 | $75.79 | $1.4M | 212,761 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -9,265 | $76.94 | $713k | 203,496 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -23,082 | $77.68 | $1.8M | 180,414 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -15,825 | $78.69 | $1.2M | 164,589 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -6,050 | $79.78 | $483k | 158,539 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -7,967 | $80.65 | $643k | 150,572 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -1,206 | $81.44 | $98k | 149,366 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,750 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,251 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -26,000 | $0.00 | $0 | 0 | Oct 28, 2024 |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,000 | $0.00 | $0 | 153,000 | Oct 28, 2024 |
Questions about Greg Zante
Answered from the filings on this page, as of the latest one.
Is Greg Zante buying or selling?
In the last 12 months Greg Zante reported 0 open-market buys worth $0 and 2 open-market sells worth $2.1M on SEC Form 4; the latest was sold $1.9M of VKTX on Jan 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Greg Zante's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Greg Zante has 0.
Where does Greg Zante file Form 4?
Greg Zante has filed Form 4 at VKTX (Viking Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.